Article
Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803).
Japanese journal of clinical oncology - 1 Jun 2013
Yamada Kazuhiko, Takayama Koichi, Kawakami Satoru, Saruwatari Kouichi, Morinaga Ryotaro, Harada Taishi, Aragane Naoko, Nagata Shuya, Kishimoto Junji, Nakanishi Yoichi, Ichinose Yukito
Abstract excerpt
OBJECTIVE: Erlotinib has been reported to be useful for treatment of non-small-cell lung cancer harboring mutation of the epidermal growth factor receptor gene EGFR-mt. However, no prospective trial has yet assessed the utility of erlotinib in Japanese patients. METHODS: Patients with EGFR-mt (exon 19/21) non-small-cell lung cancer who had previously received one to two chemotherapy regimens were enrolled in this...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.